Prime Medicine Inc’s recent filing unveils that its 10% Owner GV 2021 GP, L.L.C. acquired Company’s shares for reported $4.95 million on Aug 01 ’25. In the deal valued at $3.30 per share,1,500,000 shares were bought. As a result of this transaction, GV 2021 GP, L.L.C. now holds 3,262,440 shares worth roughly $12.36 million.
Then, NELSEN ROBERT bought 3,030,300 shares, generating $9,999,990 in total proceeds. Upon buying the shares at $3.30, the Director now owns 6,230,300 shares.
Before that, ARCH Venture Partners XII, LLC bought 3,030,300 shares. Prime Medicine Inc shares valued at $9,999,990 were divested by the 10% Owner at a price of $3.30 per share. As a result of the transaction, ARCH Venture Partners XII, LLC now holds 6,230,300 shares, worth roughly $23.61 million.
Citigroup downgraded its Prime Medicine Inc [PRME] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid May from “an Overweight” to “a Neutral”. H.C. Wainwright also remained covering PRME and has decreased its forecast on May 20, 2025 with a “Neutral” recommendation from previously “Buy” rating. JMP Securities started covering the stock on December 10, 2024. It rated PRME as “a Mkt outperform”.
Price Performance Review of PRME
On Friday, Prime Medicine Inc [NASDAQ:PRME] saw its stock jump 2.85% to $3.79. Over the last five days, the stock has lost -6.31%. Prime Medicine Inc shares have fallen nearly -16.26% since the year began. Nevertheless, the stocks have risen 29.62% over the past one year.
How much short interest is there in Prime Medicine Inc?
A steep rise in short interest was recorded in Prime Medicine Inc stocks on 2025-07-15, growing by 3.18 million shares to a total of 21.66 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 18.48 million shares. There was a rise of 14.69%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 20, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
